GenTrust’s United Therapeutics UTHR Stock Holding History

GenTrust’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-359	Closed	-$213K	–	296
2026 Q1	$213K	Sell	359 -94	-21%	-$46.8K	0.01%	265
2025 Q4	$221K	Buy	+453	New	+$211K	0.01%	262

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

GenTrust's UTHR Position: Q2 2026 in Review

GenTrust sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 359 shares — an estimated $213K sold.

GenTrust first reported a position in UTHR in Q4 2025 and held it in 2 quarters. The position peaked at $221K in Q4 2025. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

GenTrust reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
GenTrust sold 359 United Therapeutics shares in Q2 2026, an estimated $213K.
GenTrust first reported a position in United Therapeutics in Q4 2025 and held it in 2 quarters.
GenTrust's United Therapeutics position peaked at $221K in Q4 2025.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on GenTrust's 13F filing for Q2 2026, filed 6 Aug 2026.